Overview

Pharmacokinetics of Inhaled Mannitol in Cystic Fibrosis Patients

Status:
Completed
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
The general objective of the study is to estimate the systemic pharmacokinetics of mannitol after single and multiple dosing of IDPM 400 mg to adult and paediatric cystic fibrosis patients.
Phase:
Phase 1
Details
Lead Sponsor:
Pharmaxis
Treatments:
Mannitol